Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ELAB · NASDAQ · Pharmaceutical Preparations
Pmgc (ELAB) · oqro.io/stocks/ELAB · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Pmgc is on record in SEC filings since 2006.
No open-market sale by an insider of Pmgc (ELAB) was filed with the SEC in the last 90 days.
No trade in Pmgc (ELAB) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$1.14−0.13 (−10.24%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−99.9% (−$1,143.66) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $1,144.80 on Nov 20, 2025 to $1.14 on Nov 20, 2026 (−99.9%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Newport Beach, Ca.
Last 12 months
−99.9%
Market value
$1.48M
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 19K shares sold short (1.4% of shares outstanding), +0.7% vs the previous count, 2.6 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$590K
Year ended Dec 31, 2025
Net income, fiscal 2025
−$7.75M
A loss for the year
Shares outstanding
1.17M
As of Nov 11, 2026
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Things to keep in mind
No Schedule 13D or 13G filing on ELAB over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Latest annual report filed Mar 30, 2026. Read the filing
The risk factors section was largely rewritten: most of its 91 headings have no close match among the 70 of the year before, so no list of changes is shown.
As of the date of this Annual Report, there are no active legal proceedings pending or threatened against the Company. However, from time to time, we may be subject to various legal claims and proceedings that arise from the normal course of business activities, including, third party intellectual property infringement claims against us in the form of letters and other forms of communication.
Source: SEC EDGAR, Form 10-K filed Mar 30, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Revenue
$2.53M
+784.9% vs the same quarter a year earlier
Free cash flow, last 12 months
−$10M
This quarter −$2.62M
Net debt
—
Debt —, cash $113M, at Sep 30, 2026
Net income, last 12 months
−$13.3M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
Off-exchange trading: 60.4% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (5.1% on ATS, 55.3% with other brokers), above its 8-week average of 53.4%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: IBKR ATS (21.0%), UBS ATS (17.8%), ONECHRONOS (7.4%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 13, 2026. Quarterly reports are not audited. Read the filing
No figure for the same quarter a year earlier
No figure for the same quarter a year earlier
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 5,000 words.
On December 31, 2024, the Company entered into an asset purchase agreement (the “Asset Purchase Agreement”) with an unrelated third party, pursuant to which the Company agreed to sell, and the unrelated third party agreed to purchase, the Company’s skincare business. The sale of the skincare business was consummated on January 16, 2025. Prior to entering into the Asset Purchase Agreement, the Company’s principal business was operating a skincare development company engaged in the design, manufacture, and marketing of skincare products in the skincare industry. After the sale of the skincare business, the Company changed its principal business. PMGC Holdings Inc.
And 19 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 30, 2026 and Form 10-Q filed Nov 13, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.